<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pulmonx Corp — News on 6ix</title>
<link>https://6ix.com/company/pulmonx-corp</link>
<description>Latest news and press releases for Pulmonx Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pulmonx-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835948c78dffbe2df103c40.webp</url>
<title>Pulmonx Corp</title>
<link>https://6ix.com/company/pulmonx-corp</link>
</image>
<item>
<title>Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-to-report-first-quarter-2026-financial-results-on-april-29-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-to-report-first-quarter-2026-financial-results-on-april-29-2026</guid>
<pubDate>Wed, 15 Apr 2026 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “I</description>
</item>
<item>
<title>Pulmonx Announces Closing of up to $60 Million Credit Facility</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-closing-of-up-to-dollar60-million-credit-facility-114</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-closing-of-up-to-dollar60-million-credit-facility-114</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital REDWOOD CITY, Calif., March 04, 2026</description>
</item>
<item>
<title>Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-fourth-quarter-and-full-year-2025-financial-results-133</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-fourth-quarter-and-full-year-2025-financial-results-133</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally</description>
</item>
<item>
<title>Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be availa</description>
</item>
<item>
<title>Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-inducement-grants-under-210500755</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-inducement-grants-under-210500755</guid>
<pubDate>Wed, 03 Dec 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) for an aggregate of 1,625,000 shares of Pulmonx’s common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx’s Chief Financial</description>
</item>
<item>
<title>Pulmonx Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-third-quarter-2025-210500578</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-third-quarter-2025-210500578</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in internatio</description>
</item>
<item>
<title>Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-management-transition-preliminary-200500606</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-management-transition-preliminary-200500606</guid>
<pubDate>Mon, 27 Oct 2025 20:05:00 GMT</pubDate>
<description>Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial</description>
</item>
<item>
<title>Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-report-third-quarter-2025-200500591</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-report-third-quarter-2025-200500591</guid>
<pubDate>Wed, 15 Oct 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone</description>
</item>
<item>
<title>Jaeger™ and Pulmonx Announce Strategic Partnership to Integrate Data Qualification Capabilities into SentrySuite™</title>
<link>https://6ix.com/company/pulmonx-corp/news/jaegertm-and-pulmonx-announce-strategic-partnership-to-integrate-data-qualification-capabilities-into-sentrysuitetm</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/jaegertm-and-pulmonx-announce-strategic-partnership-to-integrate-data-qualification-capabilities-into-sentrysuitetm</guid>
<pubDate>Wed, 27 Aug 2025 13:00:00 GMT</pubDate>
<description>Jaeger™ Medical, a global leader in respiratory diagnostic products, is pleased to announce a strategic partnership with Pulmonx Corporation, Redwood City, California, USA, to integrate advanced data qualification functionality into SentrySuite™, the Jaeger™ Medical industry-leading software platform for respiratory diagnostics.</description>
</item>
<item>
<title>Pulmonx to Participate in September Investor Conferences</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-participate-september-investor-conferences-200500056</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-participate-september-investor-conferences-200500056</guid>
<pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceFormat: Fireside Chat and 1x1 meetingsDate: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ETLocation: Boston, MAWebcast Link: Click here Lake Street Best Ideas Growth (BIG9) ConferenceFormat: 1x1</description>
</item>
<item>
<title>Pulmonx Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-second-quarter-2025-200500939</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-second-quarter-2025-200500939</guid>
<pubDate>Wed, 30 Jul 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15% increase over the same period last year and an increase of 13% on a constant currency basisDelivered $9.1 million in internation</description>
</item>
<item>
<title>Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-present-canaccord-genuity-45th-200500822</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-present-canaccord-genuity-45th-200500822</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.c</description>
</item>
<item>
<title>Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-present-goldman-sachs-46th-200500922</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-present-goldman-sachs-46th-200500922</guid>
<pubDate>Wed, 28 May 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pul</description>
</item>
<item>
<title>Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-present-bank-america-securities-200500458</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-present-bank-america-securities-200500458</guid>
<pubDate>Thu, 01 May 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/</description>
</item>
<item>
<title>Pulmonx Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-first-quarter-2025-200500033</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-first-quarter-2025-200500033</guid>
<pubDate>Wed, 30 Apr 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in internation</description>
</item>
<item>
<title>Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-report-first-quarter-2025-200500285</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-report-first-quarter-2025-200500285</guid>
<pubDate>Wed, 16 Apr 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “I</description>
</item>
<item>
<title>Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-record-fourth-quarter-210500734</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-record-fourth-quarter-210500734</guid>
<pubDate>Wed, 19 Feb 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% incr</description>
</item>
<item>
<title>Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-partners-with-american-lung-association-to-launch-new-educational-initiatives-for-copd-patients-and-providers</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-partners-with-american-lung-association-to-launch-new-educational-initiatives-for-copd-patients-and-providers</guid>
<pubDate>Tue, 19 Nov 2024 05:00:00 GMT</pubDate>
<description>Two New Programs Aim to Improve Awareness and Support for Patients with Severe COPD/Emphysema REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation</description>
</item>
<item>
<title>Pulmonx Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-reports-third-quarter-2024-financial-results</guid>
<pubDate>Wed, 30 Oct 2024 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive</description>
</item>
<item>
<title>Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024</title>
<link>https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-presentation-of-clinical-data-from-the-aerisealr-convert-trial-and-5-year-follow-up-data-from-the-liberate-study-at-the-european-respiratory-society-congress-2024</link>
<guid isPermaLink="true">https://6ix.com/company/pulmonx-corp/news/pulmonx-announces-presentation-of-clinical-data-from-the-aerisealr-convert-trial-and-5-year-follow-up-data-from-the-liberate-study-at-the-european-respiratory-society-congress-2024</guid>
<pubDate>Mon, 09 Sep 2024 04:00:00 GMT</pubDate>
<description>CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE</description>
</item>
</channel>
</rss>